SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC). A UK randomised phase III trial

被引：0
|
作者：
Landau, D. B. [1 ]
Hughes, L. [2 ,3 ]
Ngai, Y. [2 ,3 ]
Hanna, G. G. [4 ]
Conibear, J. [5 ]
Farrelly, L. [2 ,3 ]
Counsell, N. [2 ,3 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Oncol, EH, London, England
[2] CRUK, London, England
[3] UCL Canc Trials Ctr, Inst Canc, TJ, London, England
[4] Queens Univ Belfast, Ctr Canc Res & Cell Biol, AE, Belfast, Antrim, North Ireland
[5] St Bartholomews Hosp, Barts Canc Inst, BE, London, England
来源：
LUNG CANCER | 2017年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
119
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [21] Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients
    De Rose, F.
    Cozzi, L.
    Navarria, P.
    Ascolese, A. M.
    Clerici, E.
    Infante, M.
    Alloisio, M.
    Testori, A.
    Toschi, L.
    Finocchiaro, G.
    Santoro, A.
    Scorsetti, M.
    CLINICAL ONCOLOGY, 2016, 28 (01) : 13 - 20
  • [22] Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer: Rationale and Outcomes
    Iyengar, Puneeth
    Timmerman, Robert D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (12): : 1514 - 1520
  • [23] STEREOTACTIC ABLATIVE RADIOTHERAPY OF EARLY STAGE NON-SMALL CELL LUNG CANCER
    Cvek, Jakub
    Feltl, David
    Knybel, Lukas
    Otahal, Bretislav
    Skacelikova, Eva
    Binarova, Andrea
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S537 - S537
  • [24] Feasibility of Stereotactic Ablative Radiotherapy (SABR) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)
    Woodford, Katrina
    Panettieri, Vanessa
    Trieumy Tran Le
    Senthi, Sashendra
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1467 - S1468
  • [25] Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
    Juan, Oscar
    Popat, Sanjay
    CLINICAL LUNG CANCER, 2017, 18 (06) : 595 - 606
  • [26] Stereotactic Ablative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer, Subset Analysis of a Prospective Phase II Clinical Trial
    Sutera, P.
    Kalash, R.
    Clump, D. A., II
    D'Ambrosio, D.
    Mihai, A. M.
    Burton, S. A.
    Heron, D. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (05): : 1192 - 1192
  • [27] Stereotactic Body Radiotherapy to All Sites of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Combined with Durvalumab and Tremelimumab
    Bassetti, M.
    Lang, J.
    Morris, Z.
    Morris, B.
    Eickhoff, J.
    Traynor, A.
    Campbell, T.
    Matkowskyj, K.
    Baschnagel, A.
    Leal, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2288 - S2288
  • [28] A PHASE 2 STUDY OF DURVALUMAB COMBINED WITH CHEMOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (SABRCURE TRIAL)
    Chen, Ming
    Ma, Honglian
    Du, Xianghui
    Xu, Yujin
    Ji, Yongling
    Song, Zhengbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A729 - A729
  • [29] Is stereotactic ablative radiotherapy (SABR) a safe treatment for multiple primary lung cancer (MPLC) non-small cell lung cancer (NSCLC)?
    Murray, P. F.
    Spencer, K.
    Snee, M.
    Dickinson, P.
    Jain, P.
    Clarke, K.
    Franks, K.
    LUNG CANCER, 2016, 91 : S48 - S48
  • [30] RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    De Ruysscher, D.
    LUNG CANCER, 2009, 64 : S21 - S21
12345